Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Tecan Group Ltd    TECN   CH0012100191

TECAN GROUP LTD

(TECN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Tecan : Automated metabolic analysis in photodynamic tumor therapy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:25am EDT

By Siegfried Sasshofer

Photodynamic Therapy (PDT) is being increasingly recognized as having potential for the treatment of tumors, especially dermatological. But using conventional manual methods of recording the metabolic processes that occur as a result of adding the photosensitizer to target cells has major limitations.

For a start, monitoring response processes can take up to three days, which leads to night gaps that can introduce an element of error into capturing data. Also the number of parameters is limited by the fact that it's only possible to work manually with 96-well plates.

Dr. Kristjan Plaetzer at the University of Salzburg, Austria set out to see whether there were benefits to automating the entire PDT process, from seeding cells to monitoring response processes. He used a Tecan Spark® 10M reader along with a standard plate wash. The results proved conclusively that automation increases accuracy, maximizes the number of parameters that can be tested in a single experiment and minimizes costs by saving time and money.

Dr Plaetzer's presentation of his impressive findings is essential viewing if you're the head of an academic laboratory, interested in cancer therapies or long-term research on metabolic processes. But it's also required viewing for anyone who is researching into the benefits of automation.

WATCH THE VIDEO

Disclaimer

Tecan Group AG published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2019 14:24:37 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TECAN GROUP LTD
04/18TECAN GROUP LTD : Ex-dividend day for final dividend
FA
04/16ANNUAL GENERAL MEETING 2019 : Tecan shareholders endorse all motions proposed by..
GL
04/16TECAN : Improve your workflows with automated NGS library preparation with integ..
PU
04/11Tecan strengthens development and operations organizations
GL
04/04TECAN : Major discovery or “fake news”? Don't let cytometry assays f..
PU
04/02TECAN : How to optimize NGS library QC to improve your NGS workflow
PU
03/26TECAN : State-of-the-art assays for myasthenia gravis
PU
03/26Tecan publishes 2018 Annual Report and notice of its Annual General Meeting
GL
03/22Tecan to vertically integrate supplier of key parts
GL
03/19NGS LIBRARY PREP AND QC : Five expert tricks to save time and money
PU
More news
Financials (CHF)
Sales 2019 645 M
EBIT 2019 92,5 M
Net income 2019 79,0 M
Finance 2019 311 M
Yield 2019 1,05%
P/E ratio 2019 33,86
P/E ratio 2020 28,75
EV / Sales 2019 3,56x
EV / Sales 2020 3,25x
Capitalization 2 608 M
Chart TECAN GROUP LTD
Duration : Period :
Tecan Group Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TECAN GROUP LTD
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 247  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
David Roy Martyr Chief Executive Officer
Lukas Braunschweiler Chairman
Ulrich Kanter EVP, Head-Development & Operations Division
Rudolf Eugster Chief Financial Officer
Heinrich Fischer Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
TECAN GROUP LTD15.62%2 569
CANON INC10.41%38 155
FUJIFILM HOLDINGS CORP24.76%24 184
XEROX CORP74.90%7 897
RICOH CO LTD7.35%7 480
SEIKO EPSON CORPORATION17.71%6 337